Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

February 23, 2022

Study Completion Date

February 23, 2022

Conditions
Neonatal Seizures
Interventions
DRUG

Intravenous Levetiracetam

Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.

Trial Locations (8)

35000

Néonatologie, Rennes

45100

Service de réanimation et service néonatale, Orléans

49000

Service de réanimation néonatale, Angers

51092

Service de réanimation néonatale, Reims

59037

Service de réanimation néonatale, Lille

75012

Service de réanimation néonatale et pédiatrique, Paris

76031

Service de Pédiatrie néonatale et réanimation, Rouen

37 000

Service de Néonatologie, Tours

All Listed Sponsors
collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

collaborator

Rennes University Hospital

OTHER

collaborator

Amiens University Hospital

OTHER

lead

University Hospital, Tours

OTHER

NCT02229123 - Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study | Biotech Hunter | Biotech Hunter